Home » Stocks » MNKKQ

Mallinckrodt PLC (MNKKQ)

Stock Price: $0.2500 USD 0.0000 (0.00%)
Updated May 13, 2021 12:31 PM EDT - Market open
Market Cap 22.33M
Revenue (ttm) 2.11B
Net Income (ttm) -1.04B
Shares Out 84.71M
EPS (ttm) -12.28
PE Ratio n/a
Forward PE 0.45
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $0.2500
Previous Close $0.2500
Change ($) 0.0000
Change (%) 0.00%
Day's Open 0.2640
Day's Range 0.2450 - 0.2640
Day's Volume 221,391
52-Week Range 0.0652 - 3.6600

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DUBLIN, May 3, 2021 /PRNewswire/ --  Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced data from its Phase 4, multi-center, open-label study to assess the efficacy a...

1 week ago - PRNewsWire

DUBLIN, April 30, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that data from its Phase 4 observational registry comparing the safety and e...

1 week ago - PRNewsWire

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said had received a further US$2mln from commercial partner Mallinckrodt under a deal potentially worth up to US$2bn in milestones and royalties. In 2019, ...

Other stocks mentioned: SLN
2 weeks ago - Proactive Investors

ST. LOUIS, March 29, 2021 /PRNewswire/ --  Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that its Specialty Generics division has been recognized as Manufacturin...

1 month ago - PRNewsWire

DUBLIN, March 10, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached agreement with an ad hoc group of first lien term lenders h...

2 months ago - PRNewsWire

DUBLIN, March 4, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced publication of results from its pivotal Phase 3 CONFIRM study to assess the efficacy and safet...

2 months ago - PRNewsWire

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it will receive US$2mln following the start of work on a third drug target as part of its research collaboration with Mallinckrodt. The two are focuse...

Other stocks mentioned: SLN
2 months ago - Proactive Investors

Short interest rates can be used to predict the potential direction of an individual stock. When stocks have a high short interest rate that's a good indicator that investors believe their share prices ...

Other stocks mentioned: LGND, MAC, SKT
2 months ago - Benzinga

Negative impact of COVID-19 is likely to have hurt sales of Mallinckrodt (MNKKQ) during the fourth quarter. Investors are likely to focus on bankruptcy proceedings during the earning call.

3 months ago - Zacks Investment Research

DUBLIN, Feb. 12, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it is deferring...

3 months ago - PRNewsWire

Mallinckrodt (MNKKQ) closed the most recent trading day at $0.50, moving -1.76% from the previous trading session.

3 months ago - Zacks Investment Research

DUBLIN, Jan. 29, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced that it received a score of 100 on the Human Rights Campaign Foundation's 2021 Corporate Equal...

3 months ago - PRNewsWire

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending...

3 months ago - PRNewsWire

Mallinckrodt (MNKKQ) closed the most recent trading day at $0.23, moving +1.7% from the previous trading session.

3 months ago - Zacks Investment Research

NEW YORK, Jan. 15, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending...

3 months ago - PRNewsWire

Top Ranked Value Stocks to Buy for December 21st

Other stocks mentioned: DAC, ELVT
4 months ago - Zacks Investment Research

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 17th

Other stocks mentioned: USB, WSBF
4 months ago - Zacks Investment Research

DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced findings from a large U.S. database review of patient profiles and outcomes of patients hospit...

Other stocks mentioned: MNK
5 months ago - PRNewsWire

DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from a post hoc analysis of a retrospective chart review study of terlipressin in pati...

Other stocks mentioned: MNK
5 months ago - PRNewsWire

DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced initiation of a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 E...

Other stocks mentioned: MNK
6 months ago - PRNewsWire

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from two post-hoc studies of its investigational agent terlipressin in adults with hep...

Other stocks mentioned: MNK
6 months ago - PRNewsWire

ROCKFORD, Ill.--(BUSINESS WIRE)--In April 2017, Rockford sued Mallinckrodt and Express Scripts for antitrust violations. Rockford's lawsuit seeks to return more than $10 billion...

Other stocks mentioned: MNK
6 months ago - Business Wire

DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for it...

Other stocks mentioned: MNK
6 months ago - PRNewsWire

Here's what you should know

Other stocks mentioned: MNK
7 months ago - The Motley Fool

Shares of Mallinckrodt Plc tumbled 31.2% in trading on Monday after the company said it had filed for Chapter 11 bankruptcy, in part due to a proposed billion-dollar settlement for its alleged role in t...

Other stocks mentioned: MNK
7 months ago - Market Watch

Mallinckrodt Pharmaceuticals, facing billions of dollars in legal costs over its role in the nation's opiod crisis, filed for bankruptcy early Monday.

Other stocks mentioned: MNK
7 months ago - CNN Business

Drug manufacturer Mallinckrodt PLC (NYSE: MNK) disclosed Monday that it has voluntarily initiated Chapter 11 bankruptcy proceedings in the U.S. Bankruptcy Court to restructure its operations and pare do...

Other stocks mentioned: MNK
7 months ago - Benzinga

Mallinckrodt Plc filed for bankruptcy protection on Monday in the face of lawsuits alleging it fueled the U.S. opioid epidemic and after the drugmaker lost a court battle to avoid paying higher rebates ...

Other stocks mentioned: MNK
7 months ago - Reuters

DUBLIN, Oct. 12, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that it has voluntarily initiated Chapter 11 proceedings in the U.S. Bankruptcy Court...

Other stocks mentioned: MNK
7 months ago - PRNewsWire

A House committee has issued detailed reports about some of their drug price increases.

Other stocks mentioned: AMGN, MNK, NVS
7 months ago - The Motley Fool

Terlipressin's rejection is a huge blow to the diversification effort, but likely a delay rather than a scrapping of the entire program.

Other stocks mentioned: MNK
7 months ago - Seeking Alpha

Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.

Other stocks mentioned: MNK
7 months ago - Zacks Investment Research

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S.

Other stocks mentioned: MNK
7 months ago - PRNewsWire

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock?

Other stocks mentioned: MNK
8 months ago - Zacks Investment Research

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Other stocks mentioned: MNK
8 months ago - Zacks Investment Research

The proposed law now goes to Gov. Gavin Newsom for his signature.

Other stocks mentioned: MNK, TEVA
8 months ago - The Motley Fool

ST. LOUIS, Aug. 24, 2020 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, today announced that its Specialty Generics business has been recognized as a Manuf...

Other stocks mentioned: MNK
8 months ago - PRNewsWire

Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: MNK
8 months ago - Seeking Alpha

STAINES-UPON-THAMES, United Kingdom, Aug. 10, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S.

Other stocks mentioned: MNK
9 months ago - PRNewsWire

Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.

Other stocks mentioned: MNK
9 months ago - Zacks Investment Research

Mallinckrodt plc (MNK) CEO Mark Trudeau on Q2 2020 Results - Earnings Call Transcript

Other stocks mentioned: MNK
9 months ago - Seeking Alpha

Mallinckrodt (MNK) delivered earnings and revenue surprises of 51.20% and 12.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: MNK
9 months ago - Zacks Investment Research

Shares of Mallinckrodt PLC MNK, -23.00% plunged 25% in premrket trading Tuesday, reversing an earlier gain, after the specialty pharmaceutical company swung to a large net loss, but reported an adjusted...

Other stocks mentioned: MNK
9 months ago - Market Watch

Shares of Mallinckrodt (NYSE:MNK) decreased 24% in pre-market trading after the company reported Q2 results.

Other stocks mentioned: MNK
9 months ago - Benzinga

Shares of Mallinckrodt PLC MNK, +1.34% rose 0.9% in premrket trading Tuesday, after the specialty pharmaceutical company swung to a large net loss, but reported an adjusted profit that beat expectations...

Other stocks mentioned: MNK
9 months ago - Market Watch

DUBLIN, Aug. 4, 2020 /PRNewswire/ -- Second quarter net sales of $166.5 million net of the retrospective one-time Acthar® Gel Medicaid liability; adjusted net sales of $700.9 million, a decline of 14.9%...

Other stocks mentioned: MNK
9 months ago - PRNewsWire

Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Other stocks mentioned: MNK
9 months ago - Zacks Investment Research

Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: MNK
9 months ago - Zacks Investment Research

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Other stocks mentioned: MNK
9 months ago - Zacks Investment Research

The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.

Other stocks mentioned: MNK
9 months ago - Zacks Investment Research

About MNKKQ

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1867
CEO
Mark Trudeau
Employees
3,072
Stock Exchange
OTCMKTS
Ticker Symbol
MNKKQ
Full Company Profile

Financial Performance

In 2020, Mallinckrodt's revenue was $2.21 billion, a decrease of -30.01% compared to the previous year's $3.16 billion. Losses were -$944.60 million, -5.21% less than in 2019.

Financial Statements